CY1119805T1 - Συστημα χορηγησης φαρμακων για τη χορηγηση πτωχως υδατοδιαλυτων φαρμακευτικως ενεργων ουσιων - Google Patents
Συστημα χορηγησης φαρμακων για τη χορηγηση πτωχως υδατοδιαλυτων φαρμακευτικως ενεργων ουσιωνInfo
- Publication number
- CY1119805T1 CY1119805T1 CY20171101264T CY171101264T CY1119805T1 CY 1119805 T1 CY1119805 T1 CY 1119805T1 CY 20171101264 T CY20171101264 T CY 20171101264T CY 171101264 T CY171101264 T CY 171101264T CY 1119805 T1 CY1119805 T1 CY 1119805T1
- Authority
- CY
- Cyprus
- Prior art keywords
- administration
- delivery system
- drug delivery
- aquatically
- absolute
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Η παρούσα εφεύρεση αναφέρεται σε ένα σύστημα χορήγησης φαρμάκων για τη χορήγηση πτωχώς υδατοδιαλυτής φαρμακευτικώς ενεργής ουσίας, σε μια φαρμακευτική σύνθεση που περιλαμβάνει ένα τέτοιο σύστημα χορήγησης φαρμάκων, και σε μια μέθοδο για την παρασκευή ενός τέτοιου συστήματος χορήγησης φαρμάκων. Η εφεύρεση αναφέρεται επίσης σε μια μέθοδο για τον έλεγχο του μεγέθους σωματιδίων ή/και του σχήματος σωματιδίων ή/και της κατανομής μεγέθους σωματιδίων σε ένα τέτοιο σύστημα χορήγησης φαρμάκων, και σε μια μέθοδο για την αύξηση της ικανότητας φόρτωσης φαρμάκων των σωματιδίων. Περαιτέρω η εφεύρεση αναφέρεται επίσης στη χρησιμοποίηση ενός τέτοιου συστήματος χορήγησης φαρμάκων για την παρασκευή ενός φαρμάκου για τη θεραπευτική αγωγή καρκίνου.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/SE2007/001127 WO2009078754A1 (en) | 2007-12-19 | 2007-12-19 | Drug delivery system for administration of poorly water soluble pharmaceutically active substances |
PCT/SE2008/051515 WO2009078802A1 (en) | 2007-12-19 | 2008-12-18 | Drug delivery system for administration of poorly water soluble pharmaceutically active substances |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1119805T1 true CY1119805T1 (el) | 2018-06-27 |
Family
ID=40795732
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20171101264T CY1119805T1 (el) | 2007-12-19 | 2017-12-04 | Συστημα χορηγησης φαρμακων για τη χορηγηση πτωχως υδατοδιαλυτων φαρμακευτικως ενεργων ουσιων |
CY2019021C CY2019021I1 (el) | 2007-12-19 | 2019-04-24 | Συστημα χορηγησης φαρμακων για τη χορηγηση πτωχως υδατοδιαλυτων φαρμακευτικως ενεργων ουσιων |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY2019021C CY2019021I1 (el) | 2007-12-19 | 2019-04-24 | Συστημα χορηγησης φαρμακων για τη χορηγηση πτωχως υδατοδιαλυτων φαρμακευτικως ενεργων ουσιων |
Country Status (27)
Country | Link |
---|---|
US (4) | US8999382B2 (el) |
EP (1) | EP2231189B1 (el) |
JP (1) | JP5466172B2 (el) |
KR (1) | KR101572703B1 (el) |
CN (1) | CN101951956B (el) |
AU (1) | AU2008339099B2 (el) |
BR (1) | BRPI0821740B1 (el) |
CA (1) | CA2709266C (el) |
CY (2) | CY1119805T1 (el) |
DK (1) | DK2231189T3 (el) |
EA (1) | EA015247B1 (el) |
ES (1) | ES2650242T3 (el) |
FR (1) | FR19C1030I1 (el) |
HR (1) | HRP20171796T1 (el) |
HU (1) | HUE034684T2 (el) |
LT (2) | LT2231189T (el) |
LU (1) | LUC00117I2 (el) |
MX (1) | MX2010006914A (el) |
MY (2) | MY157187A (el) |
NL (1) | NL300987I9 (el) |
NO (2) | NO2231189T3 (el) |
NZ (1) | NZ586859A (el) |
PL (1) | PL2231189T3 (el) |
PT (1) | PT2231189T (el) |
SI (1) | SI2231189T1 (el) |
WO (2) | WO2009078754A1 (el) |
ZA (1) | ZA201004685B (el) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009078754A1 (en) * | 2007-12-19 | 2009-06-25 | Ardenia Investments, Ltd. | Drug delivery system for administration of poorly water soluble pharmaceutically active substances |
WO2009078755A1 (en) | 2007-12-19 | 2009-06-25 | Ardenia Investments, Ltd. | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance |
WO2009078756A1 (en) | 2007-12-19 | 2009-06-25 | Ardenia Investments, Ltd. | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance |
CA2759332A1 (en) * | 2009-04-21 | 2010-10-28 | Selecta Biosciences, Inc. | Immunonanotherapeutics providing a th1-biased response |
DK2575876T3 (en) | 2010-05-26 | 2018-03-12 | Selecta Biosciences Inc | MULTIVALENT VACCINES WITH SYNTHETIC NANO CARRIERS |
EP2640190A4 (en) | 2010-11-05 | 2016-05-11 | Selecta Biosciences Inc | MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS |
CN103908432B (zh) * | 2013-01-02 | 2018-09-21 | 博瑞生物医药(苏州)股份有限公司 | 一种伊沙匹隆白蛋白的冻干组合物及其制备方法 |
CN112239418B (zh) * | 2019-07-18 | 2023-07-07 | 上海现代药物制剂工程研究中心有限公司 | 视黄醇类化合物及其钠盐的制备方法 |
CN112321465B (zh) * | 2019-07-18 | 2023-06-06 | 上海现代药物制剂工程研究中心有限公司 | 一种含苯基化合物、其中间体、制备方法及应用 |
WO2021259472A1 (en) * | 2020-06-24 | 2021-12-30 | Oasmia Pharmaceutical Ab | Micellar docetaxel for use in the treatment of cancer |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6096331A (en) * | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
DE19839566C2 (de) * | 1998-08-31 | 2002-01-17 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten in der Transplantationsmedizin |
US6197809B1 (en) * | 1998-12-23 | 2001-03-06 | Ardenia Investments Ltd. | Compounds for the treatment of cancer |
US6656504B1 (en) * | 1999-09-09 | 2003-12-02 | Elan Pharma International Ltd. | Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions |
SE0101702D0 (sv) * | 2001-05-15 | 2001-05-15 | Ardenia Investments Ltd | Novel potentiating compounds |
US20050191359A1 (en) * | 2001-09-28 | 2005-09-01 | Solubest Ltd. | Water soluble nanoparticles and method for their production |
US20050249786A1 (en) * | 2001-09-28 | 2005-11-10 | Solubest Ltd. | Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds |
SE0202311D0 (sv) * | 2002-07-23 | 2002-07-23 | Ardenia Investments Ltd | Novel compounds, cytotoxic preparations comprising said compounds, methods of manufacture of said preparations, as well as methods of treatment |
EP1534672B1 (en) * | 2002-07-23 | 2013-05-01 | Ardenia Investments Ltd. | Retinol derivatives, their use in the treatment of cancer and for potentiating the efficacy of other cytotoxic agents |
US7259984B2 (en) * | 2002-11-26 | 2007-08-21 | Cornell Research Foundation, Inc. | Multibit metal nanocrystal memories and fabrication |
JP2006199590A (ja) | 2003-09-04 | 2006-08-03 | Nano Career Kk | 水溶性の塩基性薬物内包ナノ粒子含有組成物 |
WO2005089106A2 (en) | 2004-02-27 | 2005-09-29 | Molecular Therapeutics, Inc. | Degradable nanoparticles |
US7871632B2 (en) | 2004-07-12 | 2011-01-18 | Adventrx Pharmaceuticals, Inc. | Compositions for delivering highly water soluble drugs |
WO2007001356A2 (en) * | 2004-09-10 | 2007-01-04 | University Of Wyoming | Nanoparticles for cytoplasmic drug delivery to cancer cells |
KR101457834B1 (ko) * | 2005-08-31 | 2014-11-05 | 아브락시스 바이오사이언스, 엘엘씨 | 증가된 안정성을 가진 수 난용성 약물의 조성물 및 제조 방법 |
WO2009078754A1 (en) | 2007-12-19 | 2009-06-25 | Ardenia Investments, Ltd. | Drug delivery system for administration of poorly water soluble pharmaceutically active substances |
WO2009078756A1 (en) * | 2007-12-19 | 2009-06-25 | Ardenia Investments, Ltd. | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance |
WO2009078755A1 (en) * | 2007-12-19 | 2009-06-25 | Ardenia Investments, Ltd. | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance |
-
2007
- 2007-12-19 WO PCT/SE2007/001127 patent/WO2009078754A1/en active Application Filing
-
2008
- 2008-12-18 PT PT88615265T patent/PT2231189T/pt unknown
- 2008-12-18 KR KR1020107015610A patent/KR101572703B1/ko active IP Right Grant
- 2008-12-18 MY MYPI2010002786A patent/MY157187A/en unknown
- 2008-12-18 CA CA2709266A patent/CA2709266C/en active Active
- 2008-12-18 EP EP08861526.5A patent/EP2231189B1/en active Active
- 2008-12-18 HU HUE08861526A patent/HUE034684T2/en unknown
- 2008-12-18 DK DK08861526.5T patent/DK2231189T3/en active
- 2008-12-18 LT LTEP08861526.5T patent/LT2231189T/lt unknown
- 2008-12-18 BR BRPI0821740-8A patent/BRPI0821740B1/pt active IP Right Grant
- 2008-12-18 AU AU2008339099A patent/AU2008339099B2/en active Active
- 2008-12-18 SI SI200831891T patent/SI2231189T1/en unknown
- 2008-12-18 NZ NZ586859A patent/NZ586859A/en unknown
- 2008-12-18 US US12/809,252 patent/US8999382B2/en active Active
- 2008-12-18 JP JP2010539385A patent/JP5466172B2/ja active Active
- 2008-12-18 EA EA200802350A patent/EA015247B1/ru unknown
- 2008-12-18 CN CN2008801270180A patent/CN101951956B/zh active Active
- 2008-12-18 MX MX2010006914A patent/MX2010006914A/es active IP Right Grant
- 2008-12-18 ES ES08861526.5T patent/ES2650242T3/es active Active
- 2008-12-18 WO PCT/SE2008/051515 patent/WO2009078802A1/en active Application Filing
- 2008-12-18 MY MYPI2010002787A patent/MY157186A/en unknown
- 2008-12-18 NO NO08861526A patent/NO2231189T3/no unknown
- 2008-12-18 PL PL08861526T patent/PL2231189T3/pl unknown
-
2010
- 2010-07-02 ZA ZA2010/04685A patent/ZA201004685B/en unknown
-
2015
- 2015-02-27 US US14/633,177 patent/US9993438B2/en not_active Ceased
-
2017
- 2017-11-20 HR HRP20171796TT patent/HRP20171796T1/hr unknown
- 2017-12-04 CY CY20171101264T patent/CY1119805T1/el unknown
-
2019
- 2019-04-24 CY CY2019021C patent/CY2019021I1/el unknown
- 2019-04-25 LT LTPA2019508C patent/LTPA2019508I1/lt unknown
- 2019-05-03 LU LU00117C patent/LUC00117I2/fr unknown
- 2019-05-06 NL NL300987C patent/NL300987I9/nl unknown
- 2019-05-06 FR FR19C1030C patent/FR19C1030I1/fr active Active
- 2019-05-08 NO NO2019023C patent/NO2019023I1/no unknown
-
2020
- 2020-06-12 US US16/899,848 patent/USRE49741E1/en active Active
-
2021
- 2021-02-17 US US17/177,550 patent/USRE49742E1/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1119805T1 (el) | Συστημα χορηγησης φαρμακων για τη χορηγηση πτωχως υδατοδιαλυτων φαρμακευτικως ενεργων ουσιων | |
Giuliano et al. | Drug-loaded biocompatible nanocarriers embedded in poloxamer 407 hydrogels as therapeutic formulations | |
Mehta et al. | Interactions with the macrophages: an emerging targeted approach using novel drug delivery systems in respiratory diseases | |
EA200802012A1 (ru) | Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением | |
Illum | Nasal drug delivery—Recent developments and future prospects | |
Borges et al. | Oral films: Current status and future perspectives II—Intellectual property, technologies and market needs | |
Wang et al. | The bone, the joints and the Balm of Gilead | |
Fang et al. | Macrophage-targeted hydroxychloroquine nanotherapeutics for rheumatoid arthritis therapy | |
WO2008103409A3 (en) | Compositions of chloroquine coupled to antibodies and to other proteins with methods for their synthesis | |
Cho et al. | 3D printing of poloxamer 407 nanogel discs and their applications in adjuvant ovarian cancer therapy | |
MX2010002409A (es) | Composiciones y metodos para la distribucion de farmacos escasamente solubles. | |
Sharma et al. | Amalgamated microneedle array bearing ribociclib-loaded transfersomes eradicates breast cancer via CD44 targeting | |
MX2013014461A (es) | Formulaciones de liberacion sostenida para el suministro de proteinas al ojo y metodos para prepararlas. | |
WO2019155416A3 (en) | A stable pharmaceutical composition of poorly soluble nonsteroidal antiandrogens | |
ATE441402T1 (de) | Verbessertes medizinprodukt | |
Bazeed et al. | Pancreatic cancer: challenges and opportunities in locoregional therapies | |
WO2006060325A3 (en) | Coated drug delivery formulations | |
CY1121145T1 (el) | Συστημα χορηγησης φαρμακων για χορηγηση μιας υδατοδιαλυτης, κατιοντικης και αμφιφιλης φαρμακευτικως ενεργης ουσιας | |
WO2014075203A1 (es) | Nanopartículas con polímero biodegradable y biocompatible plga cargadas con el fármaco de uso humano pentoxfilina | |
Smagina et al. | Polymeric gel systems cytotoxicity and drug release as key features for their effective application in various fields of addressed pharmaceuticals delivery | |
Hariharan et al. | Localized Drug Delivery Systems: An Update on Treatment Options for Head and Neck Squamous Cell Carcinomas | |
Di Mascolo et al. | μMESH-Enabled Sustained Delivery of Molecular and Nanoformulated Drugs for Glioblastoma Treatment | |
Lin et al. | Advances in microneedle-based therapy for bone disorders | |
EA201070625A1 (ru) | Система доставки лекарственного средства для введения водорастворимого катионного и амфифильного фармацевтически активного вещества | |
Caliceti et al. | Advances in drug delivery and biomaterials: Facts and vision |